Item 5. Other Information
2K characters. Original on sec.gov · Markdown
Item 5. Other Information
The following table describes contracts, instructions or written plans for the sale or purchase of our securities adopted by our directors and executive officers during the third quarter of 2024, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), referred to as Rule 10b5-1 trading plans:
| Name and Title | Action | Date of Action | Scheduled Expiration Date(1) | Aggregate Number of Securities to be Purchased or Sold(2) | ||||||||||||||||||||||
| Christopher J. Kuehn Executive Vice President and Chief Financial Officer | Adopt | 8/5/2024 | 5/9/2025 | Sale of up to 24,791(3) shares of common stock | ||||||||||||||||||||||
| Mairéad Magner Senior Vice President and Chief Human Resources Officer | Adopt | 9/4/2024 | 6/30/2025 | Sale of 7,002(4) shares of common stock |
(1) In each case a trading plan may also expire prior to the scheduled expiration date if all transactions under the trading plan are completed before the scheduled expiration date.
(2) Aggregate number of shares in this column includes shares that may be forfeited or withheld to satisfy exercise price and tax obligations at the time of vesting.
(3) This figure includes a grant of 7,477 unvested PSUs that are expected to vest during the term of the 10b5-1 plan, which are assumed to vest at 100% of the target award amount. The actual number of PSUs that may vest can vary between 0% - 200% of the target award amount, subject to the achievement of certain performance conditions as set forth in the PSU award agreement.
(4) This figure includes a grant of 1,795 unvested PSUs that are expected to vest during the term of the 10b5-1 plan, which are assumed to vest at 100% of the target award amount. The actual number of PSUs that may vest can vary between 0% - 200% of the target award amount, subject to the achievement of certain performance conditions as set forth in the PSU award agreement.
Table of Contents
Previous: Item 1A. Risk Factors · Next: Item 6. Exhibits